HIM
ANIP icon

Hillsdale Investment Management’s ANI Pharmaceuticals ANIP Stock Holding History

Hillsdale Investment Management’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-90
Closed -$7.11K – 657
2025
Q4 		$7.11K Buy
+90
New +$7.79K ﹤0.01% 625
2024
Q3 		– Sell
-90
Closed -$5.73K – 594
2024
Q2 		$5.73K Sell
90
-67,420
-100% -$4.38M ﹤0.01% 549
2024
Q1 		$4.67M Sell
67,510
-1,900
-3% -$115K 0.37% 87
2023
Q4 		$3.83M Sell
69,410
-190
-0.3% -$10.5K 0.31% 123
2023
Q3 		$4.04M Buy
69,600
+69,520
+86,900% +$4.01M 0.37% 88
2023
Q2 		$4.31K Buy
+80
New +$3.55K ﹤0.01% 458

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Hillsdale Investment Management's ANIP Position: Q1 2026 in Review

Hillsdale Investment Management sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 90 shares — an estimated $7.11K sold.

Hillsdale Investment Management first reported a position in ANIP in Q2 2023 and held it in 6 quarters. The position peaked at $4.67M in Q1 2024. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Hillsdale Investment Management reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Hillsdale Investment Management sold 90 ANI Pharmaceuticals shares in Q1 2026, an estimated $7.11K.
  • Hillsdale Investment Management first reported a position in ANI Pharmaceuticals in Q2 2023 and held it in 6 quarters.
  • Hillsdale Investment Management's ANI Pharmaceuticals position peaked at $4.67M in Q1 2024.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Hillsdale Investment Management's 13F filing for Q1 2026, filed 4 May 2026.